Prior to TILs reinfusion, patients undergo preparatory regimens, including non-myeloablative (NMA) lymphodepletion and interleukin-2 (IL-2) administration, to prime the tumor microenvironment for optimal antitumor activity of reinfused TILs. This evidence concerns the gene IL2 and neoplasm.